csirt@kutim:~/threat-intel/cve/CVE-2021-3199

Katalog CVE

CVSS 9.8 · Critical KEV · sudah dieksploitasi EPSS 19,4%

Kerentanan Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal') pada onlyoffice document server. Skor CVSS 3.1 9.8 (Critical) menurut NVD. Masuk katalog KEV CISA pada 8 Oktober 2026, artinya sudah terbukti dieksploitasi.

Deskripsi (NVD)

Directory traversal with remote code execution can occur in /upload in ONLYOFFICE Document Server before 5.6.3, when JWT is used, via a /.. sequence in an image upload parameter.

Rincian

Terbit di NVD
26 Januari 2021
Terakhir diubah
9 Oktober 2026
Status NVD
Analyzed
CVSS 3.1
9.8 (Critical), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-22: Improper Limitation of a Pathname to a Restricted Directory ('Path Traversal')
EPSS (30 hari)
19,4% peluang dieksploitasi; lebih tinggi dari 97,3% CVE lain

Known Exploited Vulnerabilities (CISA)

Nama
ONLYOFFICE Docs Server Path Traversal Vulnerability
Masuk KEV
8 Oktober 2026
Tenggat CISA
11 Oktober 2026 (untuk instansi federal AS)
Ransomware
Belum tercatat
Tindakan wajib
Apply mitigations in accordance with vendor instructions, ensuring compliance with CISA’s BOD 26-04 Prioritizing Security Updates Based on Risk (see URL in Notes) guidance and CISA’s “Forensics Triage Requirements” (see URL in Notes). Follow applicable BOD 26-04 guidance for cloud services or discontinue use of the product if mitigations are unavailable. Stakeholders are responsible for evaluating each asset's internet exposure and ensuring adherence to BOD 26-04 patching guidelines.

Produk dan versi terdampak

VendorProdukVersi terdampak
onlyoffice document server Semua versi sebelum 5.6.3

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · KEV CISA · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 10 Okt 2026, 00:25 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.